SANUWAVE Health Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNWV research report →
Range $53 – $55
Price Chart
About the company
SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration.
- CEO
- Morgan C. Frank
- IPO
- 2024
- Employees
- 55
- HQ
- Eden Prairie, MN, US
Get TickerSpark's AI analysis on SNWV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.90M
- P/E
- 5.00
- Fwd P/E
- 4.05
- PEG
- -0.12
- P/S
- 0.31
- P/B
- 4.53
- EV/EBITDA
- 3.85
- Div Yield
- 0.00%
- Gross Margin
- 75.41%
- Op Margin
- -4.54%
- Net Margin
- 6.27%
- ROE
- 113.13%
- ROIC
- -8.05%
Latest fiscal year · YoY change
- Revenue
- $44.05M+35.0%
- Gross Profit
- $33.97M+38.4%
- Op Income
- $4.95M
- Net Income
- $11.81M+137.7%
- EPS
- $1.38+119.6%
- OCF Growth
- +57.9%
- FCF Growth
- -1.6%
- 52W High
- $35.29
- 52W Low
- $1.48
- 50D MA
- $4.26
- 200D MA
- $11.68
- Beta
- 1.48
- RSI (14)
- 24
- Avg Volume
- 78.45K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SANUWAVE’s Q3 was hit hard by CMS reimbursement changes, driving a 24% revenue decline, but recurring applicator demand held up and management sees a path in hospital-based care and reimbursement advocacy.· November 11, 2026
- Q3 revenue fell 24% year over year to $8.6 million, with system sales down sharply while consumables/applicators remained resilient.
- UltraMIST system revenue dropped about 73% to $1.2 million as customers exited the market and used systems competed with new sales.
- UltraMIST applicator revenue grew 2% year over year, with unit volume up 15%, showing continued core-product demand.
- Gross margin was 77.3%, down modestly from 77.6%, while operating loss widened because of lower gross profit.
- Management said the company is focusing more on hospitals and partnership opportunities while working with CMS/RUC on the 2028 reimbursement process.
Revenue for the third quarter was $8.6 million, down 24% from $11.3 million a year ago. Gross margin was 77.3%, compared with 77.6% last year. Operating loss was $1.1 million versus operating income of $900,000 in the prior-year quarter; adjusted EBITDA was $700,000 versus $3.2 million last year, and net loss was $1.4 million versus net income of $9.7 million, though the prior-year quarter included a $6.1 million derivative gain and a $5 million patent-sale gain. UltraMIST system revenue fell about 73% to $1.2 million from $4.4 million, while applicator revenue grew about 2% and consumables/parts/accessories rose about 5% to $7.2 million. Cash and cash equivalents were $6 million at quarter-end, and current assets were $19.3 million. For the nine months ended September 30, the company paid about $4.3 million in scheduled principal, about $2.7 million in sales tax VDA payments year to date, and said it was not in compliance with its fixed charge coverage ratio at quarter-end, though it later received a waiver. Management did not give formal revenue or EPS guidance, but said the near-term remains pressured by used-system availability and reimbursement changes, and that the company’s goal is to work toward the 2028 proposed rule cycle.
Morgan C. Frank framed the quarter as primarily a CMS-driven disruption, saying reimbursement changes caused customer exits, reduced practitioner counts, and slowed capital spending. He emphasized that SANUWAVE is pivoting further toward hospital and inpatient/outpatient settings, especially pressure-injury use cases, where he believes the product can save money and reduce length of stay. He also characterized the CMS response as potentially constructive, saying the company sees an opening to work with CMS and the RUC on a better code structure rather than viewing the rule as a simple elimination of the code.
Peter Sorensen said the financial results were pressured mainly by lower system revenue, which fell about 73% to $1.2 million, while applicator revenue rose 2% and consumables revenue rose about 5% to $7.2 million. He highlighted gross margin of 77.3%, down 32 basis points, and said operating expenses were $7.7 million, about flat year over year, with non-cash stock compensation at about $1.5 million. He also noted $2.3 million in VDA sales tax payments in Q3, about $2.7 million year to date, $4.3 million in principal payments over nine months, $6 million in cash at quarter-end, and a lender waiver obtained on October 28 after a fixed charge coverage ratio default.
Analysts asked how long it might take for the market to absorb used UltraMIST systems; management said it is difficult to predict but expects it to be a factor in Q4 and possibly into early next year. On reimbursement timing, management said the next meaningful opportunity is the 2028 proposed rule, which would be published in July 2027, and that they plan to engage with CMS and the RUC for that cycle. Questions about M&A led management to say they are more focused on partnership than acquisition activity, and questions about hospital outpatient strategy drew an answer that the company has been pivoting there since last year and is now seeing progress, though sales cycles remain long.
The core applicator business remained resilient, with unit volume up 15% and revenue up 2% year over year despite the broader industry disruption. Management sees a meaningful long-term opportunity in hospital-acquired pressure injuries and says hospital sales efforts are beginning to move from evaluation into actual sales. The CEO also pointed to specific CMS/RUC language as a possible path to improve reimbursement structure rather than lose the code entirely.
The biggest risk is reimbursement: management said the CMS proposal and the resulting customer fallout materially hurt demand, especially for systems, and may continue to pressure results in Q4. System revenue collapsed 73% amid weak capital spending and used-system competition, and management said it is unsure how long that overhang will last. The company also ended the quarter with only $6 million in cash, had a covenant default that required a waiver, and is still dealing with sizable sales tax settlement payments and longer hospital sales cycles.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.6%
- Shares Outstanding
- 8.60M
- Float Shares
- 8.14M
of shares held by institutions
51 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Solas Capital Management, LLC | 610.97K | 0 |
| Vanguard Group Inc | 445.21K | ▲ 4.92K |
| Awm Investment Company, Inc. | 427.76K | ▼ 26.79K |
| Vanguard Capital Management LLC | 348.05K | ▼ 4.71K |
| Opaleye Management Inc. | 306.14K | 0 |
| Ubs Group AG | 162.09K | ▼ 94.70K |
| Blackrock, Inc. | 142.97K | ▼ 16.89K |
| Geode Capital Management, LLC | 89.70K | ▲ 3.61K |
| D. E. Shaw & Co., Inc. | 59.34K | ▲ 59.34K |
| Luxor Capital Group, LP | 58.30K | ▲ 21.10K |
| Vanguard Fiduciary Trust Co | 54.86K | ▲ 11.77K |
| Jpmorgan Chase & Co | 50.11K | ▲ 10.41K |
Held by 28 ETFs
Biggest fund positions in SNWV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 30, 26 | Opaleye Management Inc. | sell | 24,000 |
| May 1, 26 | Opaleye Management Inc. | sell | 10,081 |
| Apr 30, 26 | Opaleye Management Inc. | sell | 1,000 |
| May 1, 26 | Opaleye Management Inc. | sell | 500 |
| Apr 28, 26 | Opaleye Management Inc. | sell | 43,788 |
| Apr 29, 26 | Opaleye Management Inc. | sell | 23,360 |
| Apr 28, 26 | Opaleye Management Inc. | sell | 2,500 |
| Apr 29, 26 | Opaleye Management Inc. | sell | 1,000 |
| Apr 17, 26 | Opaleye Management Inc. | sell | 11,267 |
| Apr 21, 26 | Opaleye Management Inc. | sell | 202 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SNWV coverage
Recent articles, reports, and earnings notes.
No research on SNWV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SNWV report →Sanuwave Health Q3 Earnings Call Highlights
defenseworld.net · Nov 14
SANUWAVE Health, Inc. (SNWV) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
Sanuwave Announces Q3 FY2026 Financial Results
globenewswire.com · Nov 10
Sanuwave Will Host a Conference Call on November 11, 2026 at 8:30 AM (ET) to Present Q3 2026 Financial Results
globenewswire.com · Nov 6
Sanuwave Health Comments on 2027 Medicare Physician Fee Schedule Rate for Ultramist
globenewswire.com · Nov 5
SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 7
Sanuwave Health Q2 Earnings Call Highlights
marketbeat.com · Aug 7
Sanuwave Announces Q2 FY2026 Financial Results
globenewswire.com · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.